Wynzora is a Small Molecule owned by MC2 Therapeutics, and is involved in 7 clinical trials, which were completed.
Betamethasone is a glucocorticoid receptor (GR) agonist. Glucocorticoids bind to glucocorticoid receptors in the cytoplasm. These receptors dimerize and translocate to the nucleus, where they bind to glucocorticoid response elements (GRE) on glucocorticoid responsive genes. This results in increased transcription of genes coding for anti-inflammatory proteins. Calcipotriene acts as vitamin D3 receptor agonist. Vitamin D acts as a modulator of the immune system especially the Type 1 helper T cell (Th1) pathway and aids in treating Th1 inflammatory diseases. The drug candidate binds to the VDR and causes activation of this receptor complex causing reduction of keratinocyte proliferation by modulating the T cells gene transcription for cell differentiation and proliferation related genes.
The revenue for Wynzora is expected to reach a total of $503m through 2038. This change impacts the valuation of this asset and is an important factor to understand the current value of the drug in a clinical process. View the complete picture with the Wynzora NPV Report.
Wynzora is currently owned by MC2 Therapeutics. Almirall is the other company associated in development or marketing of Wynzora.
Betamethasone dipropionate and Calcipotriene (Wynzora, Winxory) is a fixed dose combination, in which calcipotriene is a synthetic calcitriol derivative and betamethasone dipropionate is a glucocorticoid. It is formulated as cream for topical and cutaneous route of administration. Wynzora indicated for the treatment of plaque psoriasis in adult patients aged 18 years or older.
Almirall is a specialty pharmaceutical company that researches, develops, manufactures, and commercializes proprietary medicines and licensed products. The company’s major area of focus is dermatology covering psoriasis, eczema, acne, and other skin infections. It also develops products for autoimmune diseases including rheumatoid arthritis and multiple sclerosis; and gastrointestinal diseases including irritable bowel syndrome with constipation. The company also works together with small and medium-sized companies and healthcare professionals to develop medical solutions and provide them to patients. It operates through affiliates in Europe and Central America and has R&D centers in Spain and Germany. Almirall is headquartered in Barcelona, Spain.
The company reported revenues of (Euro) EUR827.2 million for the fiscal year ended December 2021 (FY2021), an increase of 2.4% over FY2020. In FY2021, the company’s operating margin was 0.7%, compared to an operating margin of 11.4% in FY2020. The net loss of the company was EUR40.9 million in FY2021, compared to a net profit of EUR74.3 million in FY2020. The company reported revenues of EUR197.2 million for the third quarter ended September 2022, a decrease of 54.8% over the previous quarter.
Quick View – Wynzora
|Highest Development Stage|